Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. Company
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo I-Mab
I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Number of employees : 228 people.
Sales per Business
20192020Delta
Transformational Biologics4.34100%223.50100% +5047.91%
USD in Million
Sales per region
20192020Delta
China4.34100%223.50100% +5047.91%
USD in Million
Managers
Name Title Age Since
Hua Qiong Shen Chief Executive Officer & Director 58 2019
Zheru Zhang President & Director 57 2017
Jielun Zhu Chief Financial Officer & Director 44 2019
Lili Qian Vice President-Operations 38 2019
Wei Fu Independent Director 37 -
Chun Kwok Au Independent Director 47 2020
Chia Hung Yang Independent Director 57 2020
Pamela M. Klein, Dr. Independent Director 58 2020
Bing Yuan Independent Director 53 -
Ruyi He Independent Director 59 2021
Members of the board
Name Title Age Since
Jing Wu Zang Chairman 64 2021
Hua Qiong Shen Chief Executive Officer & Director 58 2019
Zheru Zhang President & Director 57 2017
Jielun Zhu Chief Financial Officer & Director 44 2019
Wei Fu Independent Director 37 -
Meng Jiao Jiang Director 39 2017
Jie Yu Director 45 2019
Chun Kwok Au Independent Director 47 2020
Chia Hung Yang Independent Director 57 2020
Pamela M. Klein, Dr. Independent Director 58 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 165,477,619 163,293,638 98.7% 0 0.0% 98.7%
Shareholders
NameEquities%
HHLR Advisors Ltd. 7,182,850 9.33%
Cederberg Capital Ltd. 2,047,270 2.66%
Ward Ferry Management Ltd. 1,791,496 2.33%
Snow Lake Capital (HK) Ltd. 1,190,737 1.55%
Zeal Asset Management Ltd. 987,851 1.28%
Octagon Capital Advisors LP 943,156 1.23%
T. Rowe Price Associates, Inc. (Investment Management) 845,152 1.10%
Adage Capital Management LP 824,906 1.07%
Principal Global Investors LLC 764,363 0.99%
Invus Public Equities Advisors LLC 750,000 0.97%
Brand Portfolio
In partnership withAllbrands.markets
More brands of I-Mab
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
I-MAB39.62%5 066
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657
MERCK & CO., INC.-4.24%198 283
ABBVIE INC.2.03%193 205
ASTRAZENECA PLC20.08%187 492
NOVARTIS AG-8.03%186 330
BRISTOL-MYERS SQUIBB COMPANY-5.92%129 683
SANOFI6.53%122 086
AMGEN INC.-9.60%118 022
GLAXOSMITHKLINE PLC4.29%96 396
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-27.49%57 462
BAYER AG-0.56%54 575
JIANGSU HENGRUI MEDICINE CO., LTD.-46.12%49 566
DAIICHI SANKYO COMPANY, LIMITED-16.76%49 400
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.93%44 517
ASTELLAS PHARMA INC.25.60%32 494